Guardant Health to Present Real-World Data Supporting Performance of Shield Blood Test for Colorectal Cancer Screening at 2024 Digestive Disease Week
Palo Alto, California - Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, is set to showcase the results of two real-world studies at the upcoming 2024 Digestive Disease Week (DDW) meeting in Washington, DC. The focus will be on the effectiveness of Guardant Health’s Shield blood test in colorectal cancer (CRC) screening. With one in three eligible American adults remaining unscreened for CRC due to the unpleasant or inconvenient nature of current methods, this breakthrough presents a significant advancement in the field.
The company’s Shield test offers a non-invasive and patient-friendly alternative to traditional screening methods. By detecting colorectal cancer through a simple blood test, Guardant Health is making strides in improving the accessibility and acceptance of CRC screening. The presented real-world data will highlight the value and reliability of the Shield test, providing a strong case for its integration into routine screening protocols.
In addition to this groundbreaking announcement, the company has also reported their financial results for the first quarter of 2024. Guardant Health recorded a revenue of $168.5 million during this period, a remarkable 31% increase compared to the first quarter of 2023. The company also reported an increase of 20% in tests conducted for clinical customers and a robust 37% increase in tests performed for biopharmaceutical customers.
AmirAli, CEO of Guardant Health, expressed optimism about the future and stated, We are pleased to see the continued momentum in our business as we strive to improve patient care through precision oncology.
Furthermore, Guardant Health achieved a significant milestone by surpassing 500 peer-reviewed publications featuring their cutting-edge technology in esteemed scientific journals. The company’s liquid biopsy research studies have had a profound impact on the field of oncology and solidify Guardant Health’s position as a leader in precision medicine.
Guardant Health’s dedication to advancing cancer detection and treatment is evident through their research-driven approach and commitment to improving patient outcomes. With their groundbreaking Shield blood test and a strong portfolio of peer-reviewed publications, Guardant Health is set to revolutionize CRC screening and transform the field of precision oncology.
Comments